2,2,6,6-tetramethylpiperazine | 38515-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2,2,6,6-tetramethylpiperazine
• CAS: 38515-26-3
• 化学式: C₈H₁₈N₂
• mdl: MFCD19217706
• 分子量: 142.244
• InChiKey: ADVWVIQNAOXLCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2,6,6-tetramethylpiperazine 、 7-chloro-5-(chlorocarbonyl)-4,5-dihydroimidazo<1,5-a>quinoxaline-3-carboxylic acid 1,1-dimethylethyl ester 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 tert-butyl 7-chloro-5-(3,3,5,5-tetramethylpiperazine-1-carbonyl)-4H-imidazo[1,5-a]quinoxaline-3-carboxylate
  参考文献：
  名称：

  Piperazine Imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABA_A Ligands of Dual Functionality

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline piperazine ureas appended with a tert-butyl ester side chain at the 3-position was developed. Analogues within this series have high affinity for the gamma-aminobutyric acid A (GABA(A))/benzodiazepine receptor complex with efficacies ranging from inverse agonists to full agonists. Many analogues were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Uniquely, a number of these analogues were found to have a bell-shaped dose-response profile in the alpha(1)beta(2)gamma(2) subtype as determined by whole cell patch-clamp technique, where in vitro efficacy was found to decrease with increasing drug concentration. Many of the compounds from this series were effective in antagonizing metrazole-induced seizures, consistent with anticonvulsant and possibly anxiolytic activity. Additionally, several analogues were also effective in lowering cGMP levels (to control values) after applied stress, also consistent with anxiolytic-like properties. The most effective compounds in these screens were also active in animal models of anxiety such as the Vogel and Geller assays. The use of the piperazine substituent allowed for excellent drug levels and a long duration of action in the central nervous system for many of the quinoxalines, as determined by ex vivo assay. Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats. From this series emerged two partial agonists (55, 91) which had good activity in anxiolytic models, acceptable pharmacokinetics, and minimal benzodiazepine-type side effects.

  DOI：

  10.1021/jm9801307
• 作为产物：
  描述：

  7,15-Diaza-dispiro<5,1;5,3>hexadecan-14,16-dion 、 3,3,5,5-四甲基-2,6-哌嗪二酮 以there is obtained 2,2,6,6-tetramethylpiperazine的产率得到2,2,6,6-tetramethylpiperazine
  参考文献：
  名称：

  Alkyl alkanoate derivatives of substituted piperazines and polymer

  摘要：

  取代哌嗪的烷基烷酸酯衍生物是合成聚合材料的稳定剂，通常会因紫外线而受到恶化。这些化合物可以通过将取代哌嗪与丙烯酸酯反应或将取代哌嗪与α-卤代烷酸酯反应来形成。含有这些稳定剂的聚合物组合物也可以含有阻碍酚类化合物。一个典型的实施例是n-十八烷基-β-(15{7,15-二氮杂二环[5,1,5,3]十六烷}丙酸酯)。

  公开号：

  US03992351A1
• 作为试剂：
  描述：

  6-氯烟酸 、 N-苄基哌啶酮 在 正丁基锂 、 2,2,6,6-tetramethylpiperazine 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 5.0h， 生成 1'-苄基-6-氯-3H-螺[呋喃[3,4-C]吡啶-1,4'-哌啶]-3-酮
  参考文献：
  名称：

  EP2072519

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
  申请人：PTC THERAPEUTICS INC

  公开号：WO2020231977A1

  公开（公告）日：2020-11-19

  The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

  本描述涉及化合物、形式、以及这些化合物的药物组合物和使用这些化合物、形式或组合物治疗或改善亨廷顿病的方法。具体而言，本描述涉及公式(I)、公式(II)或公式(III)的取代单环杂环烷基化合物，以及这些化合物的形式和药物组合物，以及使用这些化合物、形式或组合物治疗或改善亨廷顿病的方法。
• [EN] 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE ET COMPOSÉS Y RELATIFS EN TANT QUE MODULATEURS POUR L'ÉPISSAGE D'ACIDES NUCLÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRANTES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006550A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds of formula (l-a) and of formula (II) and pharmaceutical compositions thereof. The present disclosure further discloses the compounds of formula (I- a) and (II) and their compositions for use in methods of modulating nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 2-(indazol-5-yl)-6-(piperidin-4-yl)-l,7- naphthyridine derivatives and similar compounds.

  本公开涉及公式(l-a)和公式(II)的化合物及其药物组合物。本公开还揭示了公式(I-a)和(II)的化合物及其组合物，用于调节核酸剪接的方法，例如，剪接预mRNA，以及用于治疗方法的化合物，例如： •增殖性疾病，如癌症、良性肿瘤或血管生成等， •神经系统疾病或障碍，如亨廷顿病等， •自身免疫性疾病或障碍、免疫缺陷性疾病或障碍、溶酶体贮积病或障碍、心血管疾病或障碍、代谢性疾病或障碍、呼吸系统疾病或障碍、肾脏疾病或障碍或传染性疾病。示例化合物包括2-(吲哚-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物和类似化合物。
• [EN] THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING<br/>[FR] DÉRIVÉS DE THIOPHÉNYLE UTILES POUR MODULER L'ÉPISSAGE D'ACIDE NUCLÉIQUE
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2021174174A1

  公开（公告）日：2021-09-02

  The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. Formula (I-b).

  本公开涉及化合物和相关组合物，其中包括调节核酸剪接，例如预mRNA的剪接，以及使用方法。公式（I-b）。
• Benzimidazole derivatives
  申请人：——

  公开号：US20040044056A1

  公开（公告）日：2004-03-04

  This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及由一般式[I]表示的化合物：1[其中，A1和A2表示选择性氟代甲基或类似物；B表示卤素，氰基，低碳烷基或类似物；D表示选择性取代的杂环基团或类似物；G表示C3-C20脂肪族基团，例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性，并且可用作镇痛剂，抗肥胖剂，脑功能改善剂，治疗阿尔茨海默病和痴呆症的药物，治疗精神分裂症和神经退行性疾病的药物，抗抑郁剂，治疗尿崩症，多尿症，低血压等的药物。
• Diaryl ketimine derivative
  申请人：Ando Makoto

  公开号：US20090247560A1

  公开（公告）日：2009-10-01

  Provided is a compound of a formula (I): [wherein R 1a and R 1b are the same or different, representing a hydrogen atom, etc.; R 2a and R 2b are the same or different, representing a hydrogen atom, etc., or R 2a and R 2b , taken together, form —CH 2 CH 2 —, R 3a and R 3b are the same or different, representing a hydrogen atom, etc.; or R 3a and R 3b , taken together, form —CH 2 CH 2 -etc.; Y 1 and Y 2 represent —C(R) 2 —, etc.; Z represents OR, NR 2 , etc.; R represents a hydrogen atom, a C 1-6 alkyl group, etc.; Ar 1 represents a 6-membered aromatic carbocyclic group, etc.; Ar 2 represents a 6-membered aromatic carbocyclic group, etc; A 3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  提供的是化合物公式(I)的复合物：[其中R1a和R1b相同或不同，代表氢原子等；R2a和R2b相同或不同，代表氢原子等，或者R2a和R2b结合形成-CH2CH2-，R3a和R3b相同或不同，代表氢原子等；或者R3a和R3b结合形成-CH2CH2-等；Y1和Y2代表-C(R)2-等；Z代表OR、NR2等；R代表氢原子、C1-6烷基等；Ar1代表6-成员芳香环烷基等；Ar2代表6-成员芳香环烷基等；A3代表6-成员芳香环烷基等。]该化合物可用作治疗中枢障碍、心血管障碍、代谢障碍的药物。